Frontage is a full-service CRO that enables biopharmaceutical and generic companies to advance their molecules from preclinical and clinical development, through commercialization. We believe partnership is what turns service into solutions. Our comprehensive laboratory services include analytical testing, product development and CTM manufacturing, DMPK, and bioanalysis Our clinical service portfolio includes early stage clinical services and biometrics.
This wide range of offerings enables us to provide a variety of solutions to your drug development challenges.
With over 20 years of experience in execution of comprehensive Phase I-IIa studies, Frontage Clinical Services has full capabilities to conduct a broad range of study types (e.g. PK, confinement and ambulatory) in support of tobacco related studies. With extensive expertise in a wide variety of delivery systems, we are well-positioned to conduct tobacco-focused clinical research studies.
DMPK studies can provide critical data during discovery and development of pharmaceutical and agrochemical products. Frontage’s DMPK services, performed in accredited facilities, can help support lead drug candidate or chemical selection, or help you meet specific regulatory requirements.
PKI Combo™ addresses the goals of both in vivo PK screening and metabolite profiling early, rapidly and economically. The key success of this service is to integrate, previously unrelated, discovery DMPK studies into one lab, using one animal study, one analytical instrument, and one study team.
Webinar: Stability Testing As A Quality Control Measure: Optimizing The Process Throughout The Product Lifecycle
Assessing a compound’s stability is a complex and lengthy process with objectives varying by the development phase. A poorly designed stability study can cause delays that extend to years, create significant budget overruns and even result in product failure. Thus, stability testing requires scientific expertise and very specialized experience in order to minimize development costs and avoid severe consequences. This webinar will discuss the purpose, scope, and type of stability testing required at each phase of product development. With this understanding, sponsors can aim to optimize the process and ensure that the right data are gathered at the right time.
ADCs (Antibody Drug Conjugates) combine the best of two modalities, toxic efficacy and antibody specificity. The result is an improved therapeutic window with fewer side effects. However, the bioanalytical requirements for PK analysis also require a multifaceted approach. Here-in we describe various mass spectrometry based strategies Frontage has successfully applied in the bioanalysis of ADC’s for clinical and preclinical studies.